Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin

US12116602B2 · kind B2 · utility

Assignee

• Mayo Foundation for Medical Education and Research · US

Inventors

• Liyi Geng · Rochester, US
• Ping Chen · Rochester, US
• William S. Brimijoin · Rochester, US
• Yang Gao · Hangzhou City, CN

Key dates

• Filing date: Sep 9, 2022
• Grant date: Oct 15, 2024
• Expiry date: Dec 9, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression. For example, methods for administering a nucleic acid encoding a wild-type or mutant butyrylcholinesterase having the ability to hydrolyze acyl ghrelin to a mammal under conditions wherein the level of acyl ghrelin within the mammal is reduced, under conditions wherein the rate of body weight gain of the mammal is reduced, under conditions wherein the mammal's level of aggression is reduced, and/or under conditions wherein the mammal's rate of developing stress-induced tissue damage are provided.